The global retinal vein occlusion treatment market is poised for significant growth, with its valuation expected to double from USD 2.3 billion in 2023 to USD 4.7 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 5.9%. Retinal vein occlusion, one of the most common retinal vascular diseases in older adults, primarily affects individuals over the age of 65. With the geriatric population on the rise, the incidence of RVO is anticipated to increase accordingly.
Key players in the RVO treatment market are enhancing their production capacities for corticosteroid drugs, which help manage the inflammatory components causing edema. Concurrently, medical professionals are becoming increasingly adept at employing focal laser therapy to reduce swelling by targeting specific areas with lasers. Additionally, substantial investments are being made in the advancement and research of pan-retinal photocoagulation therapy.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16599
Anti-vascular endothelial growth factor (anti-VEGF) medications such as Lucentis, Avastin, and Eylea are frequently used in treating BRVO cases with neovascularization or macular edema. These treatments are critical in managing the condition and improving patient outcomes.
The market is also benefiting from increased approvals of medications for RVO treatment. Notably, in September 2021, the FDA approved Byooviz (ranibizumab-nuna), the first biosimilar drug developed by Samsung Bioepis, for treating macular degeneration and other eye diseases, including RVO. This landmark approval is expected to drive significant growth in the industry.
Regional Market Insights:
North America held a substantial share of the global RVO market in 2022, owing to various factors such as advanced healthcare facilities, a high prevalence of eye disorders, cutting-edge technology, and an increasing aging population. The region’s robust infrastructure and high healthcare expenditure have been pivotal in supporting market growth.
Looking ahead, the Asia Pacific region is projected to experience the fastest growth, with a CAGR of 6.5% from 2023 to 2033. The rising prevalence of eye conditions, particularly in countries like China, Singapore, Indonesia, and other Southeast Asian nations, coupled with increasing healthcare spending, is expected to fuel market expansion in this region.
As the global population ages and the prevalence of retinal vein occlusion rises, the market for RVO treatments is set for substantial growth. Continued advancements in medical treatments and increased drug approvals will play a critical role in addressing this condition and improving the quality of life for affected individuals.
Key Takeaways from the Market Study:
- Global retinal vein occlusion treatment market to reach a valuation of US$ 4.7 billion in 2033
- East Asia retinal vein occlusion market is expected to expand at a CAGR of 6.5%.
- From 2018 to 2022, sales increased significantly at a CAGR of 5%.
- The random-effects gathered likelihood of RVO in Europeans over the age of 55 was 0.7%, according to a 2018 Pubmed report.
- The total number of affected people in the EU is expected to nearly double, from 900,000 in 2018 to 1.1 million in 2050.
“Players in the retinal vein occlusion treatment domain are increasing their capacity to produce corticosteroid drugs, which can help combat the inflammatory factors that cause edema. Healthcare professionals, on the other hand, are becoming increasingly skilled in focal laser therapy,” says FMI’s analyst.
Request Customization of Report: https://www.futuremarketinsights.com/customization-available/rep-gb-16599
Market Competition:
Key players in the retinal vein occlusion treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.
- Novartis affirmed highly supportive for the initial interpretable Phase III findings of a clinical study investigating the effectiveness and protection of Beovu in December 2020. Beovu by Novartis placed Regeneron’s anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
- Roche is presently performing Phase III trials to examine the effectiveness and security of Faricimab in sick people with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 based on the findings.
Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey:
By Drug Class:
- Ranibizumab
- Dexamethasone
- Aflibercept
- Bevacizumab
By Type:
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
By Diagnosis:
- Optical Coherence Tomography
- Fundoscopic Examination
- Fluorescein Angiography
By End User:
- Hospitals
- Research and Academics
- Specialty Clinics
By Region:
- North America
- Europe
- East Asia
- South Asia
- Oceania
- Latin America
- Middle East and Africa (MEA)
A Detailed Full Report: https://www.futuremarketinsights.com/checkout/16599
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube